Journal of Clinical Oncology
Articles in this Issue
Real-world efficacy and safety of tarlatamab in patients with relapsed extensive-stage small cell lung cancer.
8088 Background: Tarlatamab, a bispecific T cell engager targeting Delta-Like ligand 3, received FDA approval in May 2024 for patients with relapsed exten...
A phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer: Big Ten Cancer Research Consortium GI22-588.
TPS3633 Background: Anal squamous cell carcinoma (SCC) is an evolving public health challenge, with increasing incidence and mortality rates, particularly...
Health workers' and women's perspectives on barriers to cervical cancer screening and treatment uptake in North-Central Nigeria.
e17508 Background: Cervical cancer is a significant public health problem globally, particularly in sub-Saharan Africa (SSA), with an estimated 35 new cas...
Ampullary adenocarcinoma: What is the best approach? Insights from a large retrospective series.
e16473 Background: Ampullary adenocarcinoma (AAC) is rare (~0.2% of gastrointestinal cancers), but is increasing in incidence. Knowledge about risk factor...
Perioperative FLOT vs EOX regimen and non-metastatic gastric carcinoma survival outcomes: Real-world data from a tertiary cancer centre, India.
e16125 Background: Gastric carcinoma contributes to the leading cancer sites worldwide. The current standard of care is using a perioperative FLOT regimen...
Comparative efficacy of zanubrutinib (ZANU) versus fixed-duration acalabrutinib plus venetoclax (AV) for first-line treatment of chronic lymphocytic leukemia (CLL): A matching-adjusted indirect comparison (MAIC).
e19032 Background: In treatment-naive (TN) CLL, the efficacy of continuous ZANU has been investigated in the phase 3 SEQUOIA trial (NCT03336333) and effic...
Phase I/II trial of <sup>177</sup> Lu-NYM032 for progressive metastatic castration-resistant prostate cancer.
e17040 Background: Targeting Prostate-specific membrane antigen (PSMA) offers a promising therapeutic strategy for mCRPC. 177 Lu-N...
Inhibition of transcriptional cyclin-dependent kinases, CDK12/13, as a treatment for colorectal cancer with CDK12 upregulation.
e15722 Background: Cell proliferation is a hallmark of cancer growth, and regulation of transcription and translation is key to controlling proliferative...
Impact of disease progression on health-related quality of life (HRQOL): Updated results from the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line (1L) maintenance therapy in patients with newly diagnosed advanced ovarian cancer (aOC).
5551 Background: The phase 3 PRIMA trial (NCT02655016) demonstrated that niraparib 1L maintenance therapy significantly extended progression-free survival...
Care needs and considerations for implementing a community-based palliative care program for women with breast or cervical cancer in three Nigerian states.
12068 Background: Breast and cervical cancer pose a significant public health burden in most sub-Saharan African countries including Nigeria. With ~70% of...
Global disparities in patient education for radiation therapy: A cross-sectional survey of practices and gaps in low- and middle-income countries (LMICs).
e13859 Background: Effective patient education (PE) about radiation therapy (RT) is essential yet understudied in LMICs. This study evaluates practices an...
A phase II trial to evaluate clinical efficacy, pharmacodynamics and exploratory analysis of pemetrexed in relation to MLL4 and UTX alteration status in patients with relapsed/refractory metastatic urothelial carcinoma and other solid tumors.
TPS4621 Background: MLL4 (encoded by KMT2D) and UTX (encoded by KDM6A) are protein components of the epigenetic chromatin modifier complex COMPASS. MLL4 a...
Clear cell renal cancer metabolism: Secrets behind fatty acid synthesis.
e16500 Background: Clear renal cell carcinoma (KIRC) is the most common histological subtype of renal cell carcinoma, known for its clear appearance due t...
Financial toxicity and employment outcomes in people with melanoma receiving adjuvant therapies.
9577 Background: One year ofadjuvant anti-programmed cell death protein-1 (anti-PD1) or dabrafenib-trametinib are standards of care for patients (pts) wit...
Liquid biopsy-informed precision oncology clinical trial to evaluate the utility of ctDNA genomic profiling in patients with advanced or metastatic solid tumors.
3052 Background: Genomic profiling through liquid biopsies (LB) has enabled precision oncology decision making, however a key challenge lies in critically...
Comparing myeloablative and reduced-intensity conditioning for allogeneic PBSCT in MDS with increased blasts.
e18573 Background: Myelodysplastic syndrome with increased blasts (MDS-IB) is a complex hematologic malignancy characterized by ineffective hematopoiesis...
Exploring the efficacy and mechanism of action of combined pan-Raf and MEK inhibition in halting the growth of non-V600 BRAF mutated tumors.
3117 Background: Class 2 & 3 non-V600 BRAF mutations mediate RAF dimerization to hyperactivate the MAPK signaling pathway. Encorafenib (Enco; BRAF mon...
Risk factors of developing multisystem immunotherapy-related adverse events among patients with breast cancer treated with immune checkpoint inhibitors.
e14666 Background: Multisystem immune-related adverse events (MsirAEs) are defined as irAEs occurring concomitantly with another irAE or during treatment...
A phase 1/2 open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of BH-30643 in adult subjects with locally advanced or metastatic NSCLC harboring EGFR and/or HER2 mutations (SOLARA).
TPS8663 Background: Clinical outcomes for patients with metastatic EGFR -mutant NSCLC have steadily improved with successive gener...
Effect of obesity on the survival outcomes among Indian women with breast cancer.
e12558 Background: Studies have reported increased risk of breast cancer (BC) with obesity in Indian population and few studies also highlighted the assoc...
Advancing personalized medicine in primary bladder adenocarcinoma (PAB): A machine learning study.
e16617 Background: PAB is a rare and aggressive tumor with a poor prognosis. Comprising 0.5-2% of bladder cancers. This poses a significant diagnostic cha...
Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma.
2586 Background: LB1410 is a recombinant humanized anti-PD-1/TIM-3 bispecific antibody (BsAb) developed by L&L Biopharma Co., Ltd. for patients (pts)...
The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: Preliminary results from a first-in-human phase 1/2 study.
3153 Background: ACE-86225106 is a highly selective PARP1 inhibitor, exhibiting high potency in enzymatic and DNA-trapping assays of PARP1, while maintain...
Sacituzumab govitecan initial dose reduction in Polish patients with metastatic triple-negative breast cancer: Impact on efficacy and safety.
e13136 Background: Sacituzumab govitecan (SG) is approved for the treatment of metastatic triple-negative breast cancer in the ≥2 treatment line setting,...
Complementary value of a digital pathology biomarker to post-surgery circulating tumor DNA in risk stratification of stage III colon cancer patients receiving adjuvant chemotherapy.
3604 Background: The current standard of care for patients with stage III colon cancer (CC) is resection followed by adjuvant chemotherapy (ACT). About ha...